NCT00981903View on ClinicalTrials.gov

Tinzaparin for Primary Treatment and Extended Secondary Prophylaxis of Venous Thromboembolism in Patients With Cancer

PHASE2TerminatedINTERVENTIONAL
Enrollment

131

Participants

Timeline

Start Date

July 31, 2005

Primary Completion Date

October 31, 2012

Study Completion Date

October 31, 2015

Conditions
Venous ThromboembolismCancer
Interventions
DRUG

Tinzaparin sodium

Subcutaneous injection 175 U/Kg/day

Trial Locations (2)

10021

Cornell Weill Scholl of Medicine, New York

90033

University of Southern California, Los Angeles

Sponsors

Collaborators (1)

Celgene Corporation
All Listed Sponsors
collaborator

Celgene Corporation

INDUSTRY

lead

University of Southern California

OTHER